322 related articles for article (PubMed ID: 25623631)
21. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
Marlar RA; Strandberg K; Shima M; Adcock DM
Eur J Haematol; 2020 Jan; 104(1):3-14. PubMed ID: 31606899
[TBL] [Abstract][Full Text] [Related]
22. Considerations on activity assay discrepancies in factor VIII and factor IX products.
Ovanesov MV; Jackson JW; Golding B; Lee TK
J Thromb Haemost; 2021 Sep; 19(9):2102-2111. PubMed ID: 34145730
[TBL] [Abstract][Full Text] [Related]
23. Calibration of the Ph. Eur. human coagulation Factor VIII Concentrate BRP batch 6.
Raut S; Le Tallec D; Costanzo A
Pharmeur Bio Sci Notes; 2021; 2021():88-100. PubMed ID: 33973517
[TBL] [Abstract][Full Text] [Related]
24. Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP.
Pickering W; Hansen M; Kjalke M; Ezban M
J Thromb Haemost; 2016 Aug; 14(8):1579-87. PubMed ID: 27241682
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
Amiral J; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
[TBL] [Abstract][Full Text] [Related]
26. A collaborative study to establish a Korean Standard for factor VIII:C concentrate.
Kang HN; Kim SN; Lee SH; Hong SH
Thromb Res; 2004; 113(3-4):261-7. PubMed ID: 15140591
[TBL] [Abstract][Full Text] [Related]
27. A collaborative study to establish the 6th International Standard for factor VIII concentrate.
Raut S; Heath AB; Barrowcliffe TW
Thromb Haemost; 2001 Jun; 85(6):1071-8. PubMed ID: 11434687
[TBL] [Abstract][Full Text] [Related]
28. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
Ingerslev J; Jankowski MA; Weston SB; Charles LA;
J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
[TBL] [Abstract][Full Text] [Related]
29. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products.
Mikaelsson M; Oswaldsson U
Semin Thromb Hemost; 2002 Jun; 28(3):257-64. PubMed ID: 12098085
[TBL] [Abstract][Full Text] [Related]
30. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
[TBL] [Abstract][Full Text] [Related]
31. A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
Peyvandi F; Oldenburg J; Friedman KD
J Thromb Haemost; 2016 Feb; 14(2):248-61. PubMed ID: 26663865
[TBL] [Abstract][Full Text] [Related]
32. Potency estimation of recombinant factor VIII: effect of assay method and standard.
Hubbard AR; Bevan SA; Weller LJ
Br J Haematol; 2001 May; 113(2):533-6. PubMed ID: 11380427
[TBL] [Abstract][Full Text] [Related]
33. Optimization of the thrombin generation test components to measure potency of factor VIII concentrates.
Jha NK; Shestopal SA; Gourley MJ; Woodle SA; Liang Y; Sarafanov AG; Weinstein M; Ovanesov MV
Haemophilia; 2016 Sep; 22(5):780-9. PubMed ID: 27038076
[TBL] [Abstract][Full Text] [Related]
34. New BRP for human plasma calibrated for coagulation factors V, VIII, XI and XIII - collaborative study for establishment of batches 1 and 2.
Bayer P; Daas A; Milne C
Pharmeur Bio Sci Notes; 2011 Nov; 2011(2):16-25. PubMed ID: 22225765
[TBL] [Abstract][Full Text] [Related]
35. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
[TBL] [Abstract][Full Text] [Related]
36. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
Abraham S; Duncan EM
Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
[TBL] [Abstract][Full Text] [Related]
37. Standardization of assays of factor VIII and factor IX.
Barrowcliffe TW
Ric Clin Lab; 1990; 20(2):155-65. PubMed ID: 2115197
[TBL] [Abstract][Full Text] [Related]
38. Laboratory testing and standardisation.
Barrowcliffe TW
Haemophilia; 2013 Nov; 19(6):799-804. PubMed ID: 24165153
[No Abstract] [Full Text] [Related]
39. A collaborative study to establish the 7th International Standard for Factor VIII Concentrate.
Raut S; Bevan S; Hubbard AR; Sands D; Barrowcliffe TW
J Thromb Haemost; 2005 Jan; 3(1):119-26. PubMed ID: 15634275
[TBL] [Abstract][Full Text] [Related]
40. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B.
Adcock DM; Strandberg K; Shima M; Marlar RA
Int J Lab Hematol; 2018 Dec; 40(6):621-629. PubMed ID: 29979821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
